EQL Pharma（7JK）株式概要EQL Pharma AB（publish）は、スウェーデン、デンマーク、ノルウェー、フィンランド、その他ヨーロッパの薬局や病院向けにジェネリック医薬品の開発、マーケティング、販売を行っている。 詳細7JK ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長6/6過去の実績2/6財務の健全性2/6配当金0/6報酬当社が推定した公正価値より72.8%で取引されている 収益は年間67.27%増加すると予測されています リスク分析German市場と比較して、過去 3 か月間の株価の変動が非常に大きい利払いは収益で十分にカバーされない 意味のある時価総額がありません ( €61M )利益率(2.9%)は昨年より低い(11.5%) すべてのリスクチェックを見る7JK Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW482,882 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG482,882 investors already sharing narrativesYour Fair Value€Current Price€1.9451.9% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-2m1b2016201920222025202620282031Revenue SEK 1.2bEarnings SEK 35.4mAdvancedSet Fair ValueView all narrativesEQL Pharma AB (publ) 競合他社BMP Pharma TradingSymbol: BST:BMPMarket cap: €33.1mMediosSymbol: XTRA:ILM1Market cap: €300.9mLIMES SchlossklinikenSymbol: XTRA:LIKMarket cap: €159.4mDocCheckSymbol: XTRA:AJ91Market cap: €61.4m価格と性能株価の高値、安値、推移の概要EQL Pharma過去の株価現在の株価SEK 1.9452週高値SEK 8.8052週安値SEK 1.94ベータ0.251ヶ月の変化-13.98%3ヶ月変化-61.96%1年変化-74.08%3年間の変化-14.74%5年間の変化-43.16%IPOからの変化-44.46%最新ニュースお知らせ • 3hEql Pharma AB Mellozzan Approval for for Sale in KazakhstanEQL Pharma's key product Mellozzan (tablets) has been approved for sale in Kazakhstan. Approval has been obtained by EQL's regional partner, Abdi Ibrahim. The approval currently covers the 3 mg strength. The Marketing Authorisation for the 5 mg strength is expected in December 2026. The launch of both strengths is expected in the fiscal year 2027/28. Mellozzan contains the sleep hormone melatonin and is indicated for children with ADHD and suffering from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan is also indicated for the short-term treatment of jet lag in adults.お知らせ • Jul 10EQL Pharma AB (publ) to Report Q1, 2027 Results on Aug 07, 2026EQL Pharma AB (publ) announced that they will report Q1, 2027 results on Aug 07, 2026お知らせ • Jun 15EQL Pharma AB Launches Methenamine Hippurate Under Brand Name Cystohipp in GermanyEQL Pharma AB's key product methenamine hippurate has now been launched in Germany by EQL Pharma AB's license partner Dr Pfleger under the EQL Pharma AB-owned brand Cystohipp. Cystohipp is the only methenamine hippurate product that is registered in Germany. German patients with recurrent urinary tract infections will now, for the first time, have access to an equivalent alternative to antibiotics-an alternative that does not increase the risk of developing antibiotic-resistant bacteria. Since 2024, methenamine hippurate is recommended by The European Association for Urology to reduce recurrent UTI episodes in woman. Cystohipp is indicated for the prophylaxis of recurrent uncomplicated urinary tract infections, which particularly affect women due to anatomical factors. As a prophylactic treatment, Cystohipp is taken twice daily as a tablet containing 1 gram of the antiseptic substance methenamine hippurate, even when the patient does not show any symptoms of an infection. The market potential is difficult to estimate as the market is being built from scratch. However, given the clear patient and societal need for alternatives to antibiotic treatment, both EQL Pharma AB and Dr Pfleger are very optimistic about very rapid growth in Germany after launch.お知らせ • May 09+ 1 more updateEQL Pharma AB (Publ) Provides Earnings Guidance for the Year 2026/27EQL Pharma AB (publ) provided earnings guidance for the year 2026/27. Sales growth remains below the long-term target of 30%, and the EBITDA margin of 10% also falls short of the five-year plan target of 25%, mainly due to supply shortages and one-off effects.お知らせ • Apr 29EQL Pharma AB (publ) Announces Departure of Chief Supply Chain Officer Magnus Erreth, Effective Mid June 2026EQL Pharma AB (publ) announced that the current Chief Supply Chain Officer (CSCO) Magnus Erreth will leave his position. Magnus has been active in EQL Pharma since 2024 and will remain in his role until mid June 2026 and ensure a stable handover.お知らせ • Mar 26Eql Pharma AB Receives Marketing Authorization Approval for Mellozzan in ItalyEQL's key product Mellozzan® has now received Marketing Authorization approval from the health authority in Italy (AIFA), where it will be provided to patients by EQL's licensing partner Italfarmaco S.p.A. The launch of Mellozzan® in Italy is expected in the end of fiscal year 2026/27 or early 2027/28. Italy will be the second greenfield market for Mellozzan, after Germany, where EQL, with the help of Italfarmaco's local expertise and infrastructure, will build the brand and generate prescriptions. Mellozzan® contains the sleep hormone melatonin and is indicated for children with ADHD and suffering from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan® is also indicated for the short-term treatment of jet lag in adults.最新情報をもっと見るRecent updatesお知らせ • 3hEql Pharma AB Mellozzan Approval for for Sale in KazakhstanEQL Pharma's key product Mellozzan (tablets) has been approved for sale in Kazakhstan. Approval has been obtained by EQL's regional partner, Abdi Ibrahim. The approval currently covers the 3 mg strength. The Marketing Authorisation for the 5 mg strength is expected in December 2026. The launch of both strengths is expected in the fiscal year 2027/28. Mellozzan contains the sleep hormone melatonin and is indicated for children with ADHD and suffering from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan is also indicated for the short-term treatment of jet lag in adults.お知らせ • Jul 10EQL Pharma AB (publ) to Report Q1, 2027 Results on Aug 07, 2026EQL Pharma AB (publ) announced that they will report Q1, 2027 results on Aug 07, 2026お知らせ • Jun 15EQL Pharma AB Launches Methenamine Hippurate Under Brand Name Cystohipp in GermanyEQL Pharma AB's key product methenamine hippurate has now been launched in Germany by EQL Pharma AB's license partner Dr Pfleger under the EQL Pharma AB-owned brand Cystohipp. Cystohipp is the only methenamine hippurate product that is registered in Germany. German patients with recurrent urinary tract infections will now, for the first time, have access to an equivalent alternative to antibiotics-an alternative that does not increase the risk of developing antibiotic-resistant bacteria. Since 2024, methenamine hippurate is recommended by The European Association for Urology to reduce recurrent UTI episodes in woman. Cystohipp is indicated for the prophylaxis of recurrent uncomplicated urinary tract infections, which particularly affect women due to anatomical factors. As a prophylactic treatment, Cystohipp is taken twice daily as a tablet containing 1 gram of the antiseptic substance methenamine hippurate, even when the patient does not show any symptoms of an infection. The market potential is difficult to estimate as the market is being built from scratch. However, given the clear patient and societal need for alternatives to antibiotic treatment, both EQL Pharma AB and Dr Pfleger are very optimistic about very rapid growth in Germany after launch.お知らせ • May 09+ 1 more updateEQL Pharma AB (Publ) Provides Earnings Guidance for the Year 2026/27EQL Pharma AB (publ) provided earnings guidance for the year 2026/27. Sales growth remains below the long-term target of 30%, and the EBITDA margin of 10% also falls short of the five-year plan target of 25%, mainly due to supply shortages and one-off effects.お知らせ • Apr 29EQL Pharma AB (publ) Announces Departure of Chief Supply Chain Officer Magnus Erreth, Effective Mid June 2026EQL Pharma AB (publ) announced that the current Chief Supply Chain Officer (CSCO) Magnus Erreth will leave his position. Magnus has been active in EQL Pharma since 2024 and will remain in his role until mid June 2026 and ensure a stable handover.お知らせ • Mar 26Eql Pharma AB Receives Marketing Authorization Approval for Mellozzan in ItalyEQL's key product Mellozzan® has now received Marketing Authorization approval from the health authority in Italy (AIFA), where it will be provided to patients by EQL's licensing partner Italfarmaco S.p.A. The launch of Mellozzan® in Italy is expected in the end of fiscal year 2026/27 or early 2027/28. Italy will be the second greenfield market for Mellozzan, after Germany, where EQL, with the help of Italfarmaco's local expertise and infrastructure, will build the brand and generate prescriptions. Mellozzan® contains the sleep hormone melatonin and is indicated for children with ADHD and suffering from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan® is also indicated for the short-term treatment of jet lag in adults.お知らせ • Feb 13EQL Pharma AB (publ), Annual General Meeting, Aug 20, 2026EQL Pharma AB (publ), Annual General Meeting, Aug 20, 2026. Location: lund Swedenお知らせ • Dec 05+ 2 more updatesEQL Pharma AB (publ) Announces Anna Jönsson as Head of AccountingEQL Pharma AB (publ) strengthens and re-organizes its Finance Function to put more emphasis on business control and capital allocation. Current CFO, Anna Jönsson, will take on the role as Head of Accounting. Anna will continue her work in EQL by leading the accounting function and in the shorter term, focus on an ERP implementation to enhance control and simplify analysis, follow-up and reporting.お知らせ • Nov 16EQL Pharma AB (publ)'s Methenamine Hippurate Gains Marketing Approval in GermanyEQL's key product methenamine hippurate has now gained marketing approval by the Health Authorities in Germany, where it is to be provided to patients by EQL's license partner Dr Pfleger under the EQL owned brand Cystohipp. launch is planned for mid-2026. Cystohipp is the only methenamine hippurate product registered in Germany. German patients with recurrent urinary tract infections will now for the first time have access to an equivalent alternative to antibiotics. An alternative that does not increase the risk of developing antibiotic-resistant bacteria. Cystohipp is taken as a tablet containing 1 gram of the antiseptic substance methenamine hippurate. It is indicated as a prophylactic treatment for patients, mainly women, who suffer from recurrent urinary tract infections. As a prophylactic treatment, Cystohipp is taken twice daily by the patient even when the patient does not show any symptoms of an infection. The market potential is difficult to estimate as the market is being built from scratch. However, with such a clear patient and societal need for alternatives to antibiotic treatment, both and Dr. Pfleger are very optimistic about rapid growth in Germany after launch.お知らせ • Nov 06EQL Pharma AB (publ) Provides Earnings Guidance for the Full Year 2025/26EQL Pharma AB (publ) provided earnings guidance for the full year 2025/26. For the year, Sales growth is forecast at around 30%. Sales growth for the full year 2025/26 is forecast at around 15%.お知らせ • Oct 08Alexander Brising to Leave EQL Pharma as Chief Commercial Officer, Effective December 2025EQL Pharma is recruiting a new CCO with an international background as part of its new five-year plan. This means that the current Chief Commercial Officer (CCO) Alexander Brising will leave his position. Alexander has been active in EQL Pharma since 2016 and will remain in his role until the end of December 2025 and ensure a stable handover.お知らせ • Sep 24EQL Pharma AB (publ) Provides Preliminary Financial Guidance for the Second Quarter and the Full Year 2025/26EQL Pharma AB (publ) provided preliminary financial guidance for the second quarter and the full year 2025/26. For the second quarter, EQL Pharma announces that sales in the second quarter are expected to land just under SEK 90 million (85.2), that is a single-digit growth compared to the same quarter last year. Full-year results for the 2025/26 financial year are expected to be closer to 15% than 30 % growth. EQL Pharma has experienced delays in deliveries from several suppliers during the second quarter, resulting in lost sales during the quarter. Deliveries will come, but the lost sales cannot be made up for in the third and fourth quarters. The delivery delays have also led to postponements of launches that were supposed to take place in second quarter. These will instead take place towards the end of Third Quarter or early in fourth quarter. Profit is also affected, but not as significantly as sales.お知らせ • Aug 22EQL Pharma AB (publ) Elects Raymond De Vré as Board MemberEQL Pharma AB (publ) at the annual general meeting held on 21 August 2025 elected Raymond De Vré as new board member for the period until the end of the next annual general meeting.お知らせ • Aug 21Per Ollermark Announces Not Stand for Re-Election to the Board of EQL Pharma AB (publ)The current board member Per Ollermark is not available for re-election to the board of EQL Pharma AB (publ).お知らせ • Jul 02Eql Pharma AB (Publ) Announces Key Product Memprex®? (Methenamine Hemurate) License Signed with Partner for BeneluxEQL Pharma AB (publ) announced that its key product Memprex has now been licensed for sale in BeNeLux (Belgium, Netherlands, Luxemburg) with Goodlife Specialty BV. There is currently no product with methenamine hippurate offered in the BeNeLux. Memprex offers an alternative for treatment of recurring urinary tract infections which is both non-inferior to long-term antibiotics and which doesn't increase the risk to develop antibiotic-resistant bacteria since it is an antiseptic treatment rather than an antibiotic. For the exclusive rights to Memprex®? in BeNeLux, Goodlife will, subject to reaching agreed sales, pay a six-figure sum in EUR spread over six milestones.お知らせ • Jun 27EQL Pharma AB (publ) Gains Marketing Approval in FranceEQL's key product methenamine hippurate has now gained marketing approval by the Health Authorities in France, where it is to be provided to patients by EQL's license partner Laboratoires Majorelle under the EQL owned brand Altaromin. Launch is planned for early 2026, subject to reimbursement approvals. Altaromin is the only methenamine hippurate product registered in France. French patients with recurring urinary tract infections will now for the first time have access to a non-inferior alternative to antibiotics. An alternative which doesn't increase the risk to develop antibiotic-resistant bacteria.お知らせ • May 09EQL Pharma AB (publ) Provides Earnings Guidance for the Period 2025/26EQL Pharma AB (publ) provided earnings guidance for the period 2025/26. For the period, the company's Sales growth for the full year 2025/26 is forecast to be around 30%.お知らせ • May 08+ 3 more updatesEQL Pharma AB (publ) to Report Q2, 2026 Results on Nov 05, 2025EQL Pharma AB (publ) announced that they will report Q2, 2026 results on Nov 05, 2025お知らせ • Mar 07EQL Pharma AB (publ) Provides Earnings Guidance for the Period 2024/25 - 2028/29EQL Pharma AB (publ) provided earnings guidance for the period 2024/25 - 2028/29. For the period, the company's target is to increase sales at an annual growth rate of 30% (CAGR), starting with the full year 2024/25 and ending the full year 2028/29.お知らせ • Feb 05EQL Pharma AB (publ) to Report Q4, 2025 Results on May 08, 2025EQL Pharma AB (publ) announced that they will report Q4, 2025 results on May 08, 2025Reported Earnings • Nov 08Second quarter 2025 earnings released: EPS: kr0.33 (vs kr0.16 in 2Q 2024)Second quarter 2025 results: EPS: kr0.33 (up from kr0.16 in 2Q 2024). Revenue: kr85.2m (up 43% from 2Q 2024). Net income: kr9.56m (up 104% from 2Q 2024). Profit margin: 11% (up from 7.9% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 45% p.a. on average during the next 2 years, compared to a 3.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Aug 19EQL Pharma AB (publ) Appoints Nikunj A. Shah as New Board MemberEQL Pharma AB (publ) announced that at the AGM held on 19 August 2024, approved the appointment of Nikunj A. Shah as New Board Member for the period until the end of the next annual general meeting.お知らせ • Aug 13EQL Pharma AB (publ) to Report Fiscal Year 2025 Results on May 08, 2025EQL Pharma AB (publ) announced that they will report fiscal year 2025 results on May 08, 2025Reported Earnings • Aug 09First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: kr82.8m (up 47% from 1Q 2024). Net income: kr10.4m (up 53% from 1Q 2024). Profit margin: 13% (in line with 1Q 2024). Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany.New Risk • Aug 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (45% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (6.7% average weekly change).お知らせ • Jul 17EQL Pharma AB (publ), Annual General Meeting, Aug 19, 2024EQL Pharma AB (publ), Annual General Meeting, Aug 19, 2024, at 16:00 W. Europe Standard Time. Location: at the companys premises at stortorget 1, lund Swedenお知らせ • Jul 05EQL Pharma AB's Key Product Mellozzan[® ](melatonin) Receives Marketing Approval in SwitzerlandEQL Pharma AB's key product Mellozzan®? has now gained marketing approval by the Health Authorities in Switzerland, where it is to be provided to patients by EQL's license partner Medice Arzneimittel Putter GmbH & Co. KG. Launch of Mellozzan in Switzerland is planned for the financial year 2024/25, subject to reimbursement approvals and manufacturing capabilities. In addition to Switzerland the licensee also has ongoing work for registrations and subsequent launches in Finland and the UK. In 2023, Medice launched Mellozzan®? in Denmark and Norway and this year it was launched in Germany and Austria. Mellozzan®? is the first fast-acting melatonin product registered in Switzerland. Since before, slow-acting melatonin has been available for people over 55 with sleep difficulties, but nothing for Mellozzan's normal patient group - children with ADHD and insomnia where sleep hygiene measures have not been sufficient. In addition to the countries covered by Medice, other partners for Mellozzan®? are in various stages of registration in France, Italy, the Netherlands, Turkey and Kazakhstan. Furthermore, EQL has entered into a global license agreement covering about a hundred countries with Adalvo for Mellozzan.Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €5.06, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 14x in the Healthcare industry in Germany. Total returns to shareholders of 48% over the past three years.Valuation Update With 7 Day Price Move • May 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €3.61, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 17x in the Healthcare industry in Germany. Total loss to shareholders of 2.4% over the past three years.Reported Earnings • May 16Full year 2024 earnings released: EPS: kr0.78 (vs kr1.06 in FY 2023)Full year 2024 results: EPS: kr0.78 (down from kr1.06 in FY 2023). Revenue: kr264.2m (up 1.6% from FY 2023). Net income: kr22.7m (down 27% from FY 2023). Profit margin: 8.6% (down from 12% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • May 16Eql Pharma AB (Publ) Provides Sales Guidance for the Year 2024/25EQL Pharma AB (publ) provided sales guidance for the Year 2024/25. For the full year 2024/25, company project a sales growth of around 40%. Achieving this would align with company's long-term sales objectives as outlined in company's five-year financial plan.Reported Earnings • Feb 14Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: kr70.2m (down 12% from 3Q 2023). Net income: kr6.51m (down 46% from 3Q 2023). Profit margin: 9.3% (down from 15% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 47% p.a. on average during the next 2 years, while revenues in the Healthcare industry in Germany are expected to remain flat.Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Per Svangren was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Nov 25Investor sentiment improves as stock rises 31%After last week's 31% share price gain to €3.10, the stock trades at a trailing P/E ratio of 35.3x. Average trailing P/E is 20x in the Healthcare industry in Germany. Total returns to shareholders of 25% over the past year.Reported Earnings • Nov 19Second quarter 2024 earnings released: EPS: kr0.16 (vs kr0.26 in 2Q 2023)Second quarter 2024 results: EPS: kr0.16 (down from kr0.26 in 2Q 2023). Revenue: kr59.6m (down 19% from 2Q 2023). Net income: kr4.68m (down 37% from 2Q 2023). Profit margin: 7.9% (down from 10% in 2Q 2023). The decrease in margin was driven by lower revenue.Valuation Update With 7 Day Price Move • Nov 09Investor sentiment improves as stock rises 31%After last week's 31% share price gain to €2.67, the stock trades at a trailing P/E ratio of 26.9x. Average trailing P/E is 21x in the Healthcare industry in Germany. Total returns to shareholders of 12% over the past year.Valuation Update With 7 Day Price Move • Sep 07Investor sentiment deteriorates as stock falls 28%After last week's 28% share price decline to €2.53, the stock trades at a trailing P/E ratio of 27.3x. Average trailing P/E is 20x in the Healthcare industry in Germany. Total loss to shareholders of 2.3% over the past year.お知らせ • Aug 26+ 2 more updatesEQL Pharma AB (publ) to Report Fiscal Year 2024 Results on May 14, 2024EQL Pharma AB (publ) announced that they will report fiscal year 2024 results on May 14, 2024New Risk • Aug 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 32% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (32% accrual ratio). Minor Risk Market cap is less than US$100m (€66.7m market cap, or US$72.5m).Reported Earnings • Jul 26Full year 2023 earnings released: EPS: kr1.06 (vs kr1.09 in FY 2022)Full year 2023 results: EPS: kr1.06 (down from kr1.09 in FY 2022). Revenue: kr259.9m (down 37% from FY 2022). Net income: kr30.9m (down 2.0% from FY 2022). Profit margin: 12% (up from 7.7% in FY 2022). The increase in margin was driven by lower expenses.お知らせ • Jul 18EQL Pharma AB (publ) to Report Q1, 2024 Results on Aug 16, 2023EQL Pharma AB (publ) announced that they will report Q1, 2024 results on Aug 16, 2023お知らせ • Jul 07EQL Pharma AB (publ), Annual General Meeting, Aug 17, 2023EQL Pharma AB (publ), Annual General Meeting, Aug 17, 2023, at 16:00 Central European Standard Time. Location: Stortorget 1 Lund Sweden Agenda: To consider the adoption of the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet; the allocation of the company's result in accordance with the adopted balance sheet; to consider resolution on instruction and charter for the Nomination Committee; and to consider other matters.Reported Earnings • May 14Full year 2023 earnings released: EPS: kr1.06 (vs kr1.09 in FY 2022)Full year 2023 results: EPS: kr1.06 (down from kr1.09 in FY 2022). Revenue: kr259.9m (down 37% from FY 2022). Net income: kr30.9m (down 2.0% from FY 2022). Profit margin: 12% (up from 7.7% in FY 2022). The increase in margin was driven by lower expenses.Recent Insider Transactions • Mar 29Founder & Chairman recently sold €1.0m worth of stockOn the 24th of March, Christer Fahraeus sold around 300k shares on-market at roughly €3.34 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Christer's only on-market trade for the last 12 months.Reported Earnings • Nov 13Second quarter 2023 earnings released: EPS: kr0.26 (vs kr0.18 in 2Q 2022)Second quarter 2023 results: EPS: kr0.26 (up from kr0.18 in 2Q 2022). Revenue: kr73.3m (up 40% from 2Q 2022). Net income: kr7.46m (up 39% from 2Q 2022). Profit margin: 10% (in line with 2Q 2022).お知らせ • Oct 25EQL Pharma AB (publ) Launches One-Step "Lollipop" Antigen Self-Test for Covid-19 in the Nordics - All in One - One Device, One StepEQL Pharma has started to sell the brand new Alltest Covid-19 antigen self-test of the one-step "Lollipop" model, i.e. a test that, like a lollipop, is held in the mouth for two minutes. The test reads oral saliva for Covid-19 and provides an answer within 15 minutes with 99% sensitivity. This is one of the most sensitive self-tests yet for Covid-19, even more sensitive than most of the commonly used nasal swab tests. The test's simplicity and high sensitivity make it suitable for anyone who wishes to test themselves for Covid-19 infection, especially for children and others who feel discomfort from sampling in the nasal cavity. The test is CE marked and sensitive to all known variants of the Covid-19 virus, including Omicron BA.5 which is now the most common variant in Europe. The launch of the lollipop test is seen as a generation shift in EQL Pharma self-diagnostics product line and EQL is the exclusive supplier of the Alltest device in Sweden, Denmark, Finland, Norway, Germany and Ireland. The test is available in leading pharmacies.Reported Earnings • Aug 18First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr46.1m (up 24% from 1Q 2022). Net income: kr7.39m (up 196% from 1Q 2022). Profit margin: 16% (up from 6.7% in 1Q 2022). The increase in margin was driven by higher revenue.お知らせ • Aug 18+ 2 more updatesEQL Pharma AB (publ) Announces Executive ChangesEQL Pharma AB (publ) announced Christer Fåhraeus, Founder & CEO, notified the board in the autumn of 2021 that he intends to transition into a board position after the Annual General Meeting (AGM) in August 2022. At that time, the board appointed Axel Schörling, Deputy CEO, as new CEO after Fåhraeus' resignation following the AGM in August 2022. After AGM, Schörling has assumed the position as new CEO in EQL. In connection with this, Martin Kristofferson, previously Director Strategic Sourcing, has been appointed new COO.お知らせ • Jul 06+ 3 more updatesEQL Pharma AB (publ) to Report Q3, 2023 Results on Feb 14, 2023EQL Pharma AB (publ) announced that they will report Q3, 2023 results on Feb 14, 2023Reported Earnings • May 15Full year 2022 earnings released: EPS: kr1.09 (vs kr0.36 in FY 2021)Full year 2022 results: EPS: kr1.09 (up from kr0.36 in FY 2021). Revenue: kr409.8m (up 128% from FY 2021). Net income: kr31.5m (up 204% from FY 2021). Profit margin: 7.7% (up from 5.8% in FY 2021). The increase in margin was driven by higher revenue.お知らせ • May 08EQL Pharma Receives Approval of Glycopyrronium EQL Pharma Solution for Injection 0.2Mg/Ml from Danish Medicines AgencyEQL Pharma announced that it has received the approval of Glycopyrronium EQL Pharma solution for injection 0.2mg/ml from the Danish Medicines Agency and approvals in Sweden, Norway and Finland are expected shortly. Glycopyrronium EQL Pharma contains glycopyrronium bromide and is a so-called anticholinergic which is used in hospital care, among other things, to counteract salivary secretion during operations in the mouth, throat or trachea. Glycopyrronium EQL Pharma will be EQL's third approved inpatient care product and will be sold through public tenderering in all four Nordic countries. The launch is dependent on the result of tenders for procurements but can take place at the earliest in the fourth quarter (January-March) of EQL's financial year.お知らせ • Apr 26EQL Pharma AB (publ) to Report Fiscal Year 2022 Results on May 13, 2022EQL Pharma AB (publ) announced that they will report fiscal year 2022 results on May 13, 2022Valuation Update With 7 Day Price Move • Mar 28Investor sentiment improved over the past weekAfter last week's 15% share price gain to €3.20, the stock trades at a trailing P/E ratio of 52.8x. Average trailing P/E is 18x in the Healthcare industry in Germany.Valuation Update With 7 Day Price Move • Feb 23Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €2.87, the stock trades at a trailing P/E ratio of 48.5x. Average trailing P/E is 19x in the Healthcare industry in Germany.Reported Earnings • Feb 19Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: kr0.59 (up from kr0.07 in 3Q 2021). Revenue: kr117.6m (up 297% from 3Q 2021). Net income: kr17.2m (up kr15.0m from 3Q 2021). Profit margin: 15% (up from 7.3% in 3Q 2021). Revenue was in line with analyst estimates.Reported Earnings • Nov 12Second quarter 2022 earnings releasedThe company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2022 results: Revenue: kr52.5m (up 117% from 2Q 2021). Net income: kr5.35m (up 65% from 2Q 2021). Profit margin: 10% (down from 13% in 2Q 2021).Reported Earnings • Jul 21Full year 2021 earnings released: EPS kr0.36 (vs kr0.09 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: kr179.8m (up 150% from FY 2020). Net income: kr10.4m (up 284% from FY 2020). Profit margin: 5.8% (up from 3.8% in FY 2020).株主還元7JKDE HealthcareDE 市場7D-4.9%-1.0%0.7%1Y-74.1%-1.0%0.6%株主還元を見る業界別リターン: 7JK過去 1 年間で-1 % の収益を上げたGerman Healthcare業界を下回りました。リターン対市場: 7JKは、過去 1 年間で0.6 % のリターンを上げたGerman市場を下回りました。価格変動Is 7JK's price volatile compared to industry and market?7JK volatility7JK Average Weekly Movement15.1%Healthcare Industry Average Movement5.2%Market Average Movement5.4%10% most volatile stocks in DE Market12.8%10% least volatile stocks in DE Market2.8%安定した株価: 7JKの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 7JKの 週次ボラティリティ は、過去 1 年間で9%から15%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト200660Axel Schorlingwww.eqlpharma.comEQL Pharma AB (publish)は、スウェーデン、デンマーク、ノルウェー、フィンランド、その他ヨーロッパの薬局や病院向けにジェネリック医薬品の開発、マーケティング、販売を行っている。入院治療用の注射剤と外来治療用の製剤を提供している。EQL Pharma AB（publ）は2006年に設立され、スウェーデンのルンドに本社を置いている。もっと見るEQL Pharma AB (publ) 基礎のまとめEQL Pharma の収益と売上を時価総額と比較するとどうか。7JK 基礎統計学時価総額€60.59m収益（TTM）€1.14m売上高(TTM)€39.37m53.1xPER（株価収益率1.5xP/Sレシオ7JK は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計7JK 損益計算書（TTM）収益SEK 432.66m売上原価SEK 269.82m売上総利益SEK 162.84mその他の費用SEK 150.30m収益SEK 12.54m直近の収益報告Mar 31, 2026次回決算日Aug 07, 2026一株当たり利益（EPS）0.42グロス・マージン37.64%純利益率2.90%有利子負債／自己資本比率167.9%7JK の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/15 07:00終値2026/07/15 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋EQL Pharma AB (publ) 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Erik HultgårdDNB Carnegie Commissioned Research
お知らせ • 3hEql Pharma AB Mellozzan Approval for for Sale in KazakhstanEQL Pharma's key product Mellozzan (tablets) has been approved for sale in Kazakhstan. Approval has been obtained by EQL's regional partner, Abdi Ibrahim. The approval currently covers the 3 mg strength. The Marketing Authorisation for the 5 mg strength is expected in December 2026. The launch of both strengths is expected in the fiscal year 2027/28. Mellozzan contains the sleep hormone melatonin and is indicated for children with ADHD and suffering from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan is also indicated for the short-term treatment of jet lag in adults.
お知らせ • Jul 10EQL Pharma AB (publ) to Report Q1, 2027 Results on Aug 07, 2026EQL Pharma AB (publ) announced that they will report Q1, 2027 results on Aug 07, 2026
お知らせ • Jun 15EQL Pharma AB Launches Methenamine Hippurate Under Brand Name Cystohipp in GermanyEQL Pharma AB's key product methenamine hippurate has now been launched in Germany by EQL Pharma AB's license partner Dr Pfleger under the EQL Pharma AB-owned brand Cystohipp. Cystohipp is the only methenamine hippurate product that is registered in Germany. German patients with recurrent urinary tract infections will now, for the first time, have access to an equivalent alternative to antibiotics-an alternative that does not increase the risk of developing antibiotic-resistant bacteria. Since 2024, methenamine hippurate is recommended by The European Association for Urology to reduce recurrent UTI episodes in woman. Cystohipp is indicated for the prophylaxis of recurrent uncomplicated urinary tract infections, which particularly affect women due to anatomical factors. As a prophylactic treatment, Cystohipp is taken twice daily as a tablet containing 1 gram of the antiseptic substance methenamine hippurate, even when the patient does not show any symptoms of an infection. The market potential is difficult to estimate as the market is being built from scratch. However, given the clear patient and societal need for alternatives to antibiotic treatment, both EQL Pharma AB and Dr Pfleger are very optimistic about very rapid growth in Germany after launch.
お知らせ • May 09+ 1 more updateEQL Pharma AB (Publ) Provides Earnings Guidance for the Year 2026/27EQL Pharma AB (publ) provided earnings guidance for the year 2026/27. Sales growth remains below the long-term target of 30%, and the EBITDA margin of 10% also falls short of the five-year plan target of 25%, mainly due to supply shortages and one-off effects.
お知らせ • Apr 29EQL Pharma AB (publ) Announces Departure of Chief Supply Chain Officer Magnus Erreth, Effective Mid June 2026EQL Pharma AB (publ) announced that the current Chief Supply Chain Officer (CSCO) Magnus Erreth will leave his position. Magnus has been active in EQL Pharma since 2024 and will remain in his role until mid June 2026 and ensure a stable handover.
お知らせ • Mar 26Eql Pharma AB Receives Marketing Authorization Approval for Mellozzan in ItalyEQL's key product Mellozzan® has now received Marketing Authorization approval from the health authority in Italy (AIFA), where it will be provided to patients by EQL's licensing partner Italfarmaco S.p.A. The launch of Mellozzan® in Italy is expected in the end of fiscal year 2026/27 or early 2027/28. Italy will be the second greenfield market for Mellozzan, after Germany, where EQL, with the help of Italfarmaco's local expertise and infrastructure, will build the brand and generate prescriptions. Mellozzan® contains the sleep hormone melatonin and is indicated for children with ADHD and suffering from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan® is also indicated for the short-term treatment of jet lag in adults.
お知らせ • 3hEql Pharma AB Mellozzan Approval for for Sale in KazakhstanEQL Pharma's key product Mellozzan (tablets) has been approved for sale in Kazakhstan. Approval has been obtained by EQL's regional partner, Abdi Ibrahim. The approval currently covers the 3 mg strength. The Marketing Authorisation for the 5 mg strength is expected in December 2026. The launch of both strengths is expected in the fiscal year 2027/28. Mellozzan contains the sleep hormone melatonin and is indicated for children with ADHD and suffering from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan is also indicated for the short-term treatment of jet lag in adults.
お知らせ • Jul 10EQL Pharma AB (publ) to Report Q1, 2027 Results on Aug 07, 2026EQL Pharma AB (publ) announced that they will report Q1, 2027 results on Aug 07, 2026
お知らせ • Jun 15EQL Pharma AB Launches Methenamine Hippurate Under Brand Name Cystohipp in GermanyEQL Pharma AB's key product methenamine hippurate has now been launched in Germany by EQL Pharma AB's license partner Dr Pfleger under the EQL Pharma AB-owned brand Cystohipp. Cystohipp is the only methenamine hippurate product that is registered in Germany. German patients with recurrent urinary tract infections will now, for the first time, have access to an equivalent alternative to antibiotics-an alternative that does not increase the risk of developing antibiotic-resistant bacteria. Since 2024, methenamine hippurate is recommended by The European Association for Urology to reduce recurrent UTI episodes in woman. Cystohipp is indicated for the prophylaxis of recurrent uncomplicated urinary tract infections, which particularly affect women due to anatomical factors. As a prophylactic treatment, Cystohipp is taken twice daily as a tablet containing 1 gram of the antiseptic substance methenamine hippurate, even when the patient does not show any symptoms of an infection. The market potential is difficult to estimate as the market is being built from scratch. However, given the clear patient and societal need for alternatives to antibiotic treatment, both EQL Pharma AB and Dr Pfleger are very optimistic about very rapid growth in Germany after launch.
お知らせ • May 09+ 1 more updateEQL Pharma AB (Publ) Provides Earnings Guidance for the Year 2026/27EQL Pharma AB (publ) provided earnings guidance for the year 2026/27. Sales growth remains below the long-term target of 30%, and the EBITDA margin of 10% also falls short of the five-year plan target of 25%, mainly due to supply shortages and one-off effects.
お知らせ • Apr 29EQL Pharma AB (publ) Announces Departure of Chief Supply Chain Officer Magnus Erreth, Effective Mid June 2026EQL Pharma AB (publ) announced that the current Chief Supply Chain Officer (CSCO) Magnus Erreth will leave his position. Magnus has been active in EQL Pharma since 2024 and will remain in his role until mid June 2026 and ensure a stable handover.
お知らせ • Mar 26Eql Pharma AB Receives Marketing Authorization Approval for Mellozzan in ItalyEQL's key product Mellozzan® has now received Marketing Authorization approval from the health authority in Italy (AIFA), where it will be provided to patients by EQL's licensing partner Italfarmaco S.p.A. The launch of Mellozzan® in Italy is expected in the end of fiscal year 2026/27 or early 2027/28. Italy will be the second greenfield market for Mellozzan, after Germany, where EQL, with the help of Italfarmaco's local expertise and infrastructure, will build the brand and generate prescriptions. Mellozzan® contains the sleep hormone melatonin and is indicated for children with ADHD and suffering from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan® is also indicated for the short-term treatment of jet lag in adults.
お知らせ • Feb 13EQL Pharma AB (publ), Annual General Meeting, Aug 20, 2026EQL Pharma AB (publ), Annual General Meeting, Aug 20, 2026. Location: lund Sweden
お知らせ • Dec 05+ 2 more updatesEQL Pharma AB (publ) Announces Anna Jönsson as Head of AccountingEQL Pharma AB (publ) strengthens and re-organizes its Finance Function to put more emphasis on business control and capital allocation. Current CFO, Anna Jönsson, will take on the role as Head of Accounting. Anna will continue her work in EQL by leading the accounting function and in the shorter term, focus on an ERP implementation to enhance control and simplify analysis, follow-up and reporting.
お知らせ • Nov 16EQL Pharma AB (publ)'s Methenamine Hippurate Gains Marketing Approval in GermanyEQL's key product methenamine hippurate has now gained marketing approval by the Health Authorities in Germany, where it is to be provided to patients by EQL's license partner Dr Pfleger under the EQL owned brand Cystohipp. launch is planned for mid-2026. Cystohipp is the only methenamine hippurate product registered in Germany. German patients with recurrent urinary tract infections will now for the first time have access to an equivalent alternative to antibiotics. An alternative that does not increase the risk of developing antibiotic-resistant bacteria. Cystohipp is taken as a tablet containing 1 gram of the antiseptic substance methenamine hippurate. It is indicated as a prophylactic treatment for patients, mainly women, who suffer from recurrent urinary tract infections. As a prophylactic treatment, Cystohipp is taken twice daily by the patient even when the patient does not show any symptoms of an infection. The market potential is difficult to estimate as the market is being built from scratch. However, with such a clear patient and societal need for alternatives to antibiotic treatment, both and Dr. Pfleger are very optimistic about rapid growth in Germany after launch.
お知らせ • Nov 06EQL Pharma AB (publ) Provides Earnings Guidance for the Full Year 2025/26EQL Pharma AB (publ) provided earnings guidance for the full year 2025/26. For the year, Sales growth is forecast at around 30%. Sales growth for the full year 2025/26 is forecast at around 15%.
お知らせ • Oct 08Alexander Brising to Leave EQL Pharma as Chief Commercial Officer, Effective December 2025EQL Pharma is recruiting a new CCO with an international background as part of its new five-year plan. This means that the current Chief Commercial Officer (CCO) Alexander Brising will leave his position. Alexander has been active in EQL Pharma since 2016 and will remain in his role until the end of December 2025 and ensure a stable handover.
お知らせ • Sep 24EQL Pharma AB (publ) Provides Preliminary Financial Guidance for the Second Quarter and the Full Year 2025/26EQL Pharma AB (publ) provided preliminary financial guidance for the second quarter and the full year 2025/26. For the second quarter, EQL Pharma announces that sales in the second quarter are expected to land just under SEK 90 million (85.2), that is a single-digit growth compared to the same quarter last year. Full-year results for the 2025/26 financial year are expected to be closer to 15% than 30 % growth. EQL Pharma has experienced delays in deliveries from several suppliers during the second quarter, resulting in lost sales during the quarter. Deliveries will come, but the lost sales cannot be made up for in the third and fourth quarters. The delivery delays have also led to postponements of launches that were supposed to take place in second quarter. These will instead take place towards the end of Third Quarter or early in fourth quarter. Profit is also affected, but not as significantly as sales.
お知らせ • Aug 22EQL Pharma AB (publ) Elects Raymond De Vré as Board MemberEQL Pharma AB (publ) at the annual general meeting held on 21 August 2025 elected Raymond De Vré as new board member for the period until the end of the next annual general meeting.
お知らせ • Aug 21Per Ollermark Announces Not Stand for Re-Election to the Board of EQL Pharma AB (publ)The current board member Per Ollermark is not available for re-election to the board of EQL Pharma AB (publ).
お知らせ • Jul 02Eql Pharma AB (Publ) Announces Key Product Memprex®? (Methenamine Hemurate) License Signed with Partner for BeneluxEQL Pharma AB (publ) announced that its key product Memprex has now been licensed for sale in BeNeLux (Belgium, Netherlands, Luxemburg) with Goodlife Specialty BV. There is currently no product with methenamine hippurate offered in the BeNeLux. Memprex offers an alternative for treatment of recurring urinary tract infections which is both non-inferior to long-term antibiotics and which doesn't increase the risk to develop antibiotic-resistant bacteria since it is an antiseptic treatment rather than an antibiotic. For the exclusive rights to Memprex®? in BeNeLux, Goodlife will, subject to reaching agreed sales, pay a six-figure sum in EUR spread over six milestones.
お知らせ • Jun 27EQL Pharma AB (publ) Gains Marketing Approval in FranceEQL's key product methenamine hippurate has now gained marketing approval by the Health Authorities in France, where it is to be provided to patients by EQL's license partner Laboratoires Majorelle under the EQL owned brand Altaromin. Launch is planned for early 2026, subject to reimbursement approvals. Altaromin is the only methenamine hippurate product registered in France. French patients with recurring urinary tract infections will now for the first time have access to a non-inferior alternative to antibiotics. An alternative which doesn't increase the risk to develop antibiotic-resistant bacteria.
お知らせ • May 09EQL Pharma AB (publ) Provides Earnings Guidance for the Period 2025/26EQL Pharma AB (publ) provided earnings guidance for the period 2025/26. For the period, the company's Sales growth for the full year 2025/26 is forecast to be around 30%.
お知らせ • May 08+ 3 more updatesEQL Pharma AB (publ) to Report Q2, 2026 Results on Nov 05, 2025EQL Pharma AB (publ) announced that they will report Q2, 2026 results on Nov 05, 2025
お知らせ • Mar 07EQL Pharma AB (publ) Provides Earnings Guidance for the Period 2024/25 - 2028/29EQL Pharma AB (publ) provided earnings guidance for the period 2024/25 - 2028/29. For the period, the company's target is to increase sales at an annual growth rate of 30% (CAGR), starting with the full year 2024/25 and ending the full year 2028/29.
お知らせ • Feb 05EQL Pharma AB (publ) to Report Q4, 2025 Results on May 08, 2025EQL Pharma AB (publ) announced that they will report Q4, 2025 results on May 08, 2025
Reported Earnings • Nov 08Second quarter 2025 earnings released: EPS: kr0.33 (vs kr0.16 in 2Q 2024)Second quarter 2025 results: EPS: kr0.33 (up from kr0.16 in 2Q 2024). Revenue: kr85.2m (up 43% from 2Q 2024). Net income: kr9.56m (up 104% from 2Q 2024). Profit margin: 11% (up from 7.9% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 45% p.a. on average during the next 2 years, compared to a 3.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Aug 19EQL Pharma AB (publ) Appoints Nikunj A. Shah as New Board MemberEQL Pharma AB (publ) announced that at the AGM held on 19 August 2024, approved the appointment of Nikunj A. Shah as New Board Member for the period until the end of the next annual general meeting.
お知らせ • Aug 13EQL Pharma AB (publ) to Report Fiscal Year 2025 Results on May 08, 2025EQL Pharma AB (publ) announced that they will report fiscal year 2025 results on May 08, 2025
Reported Earnings • Aug 09First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: kr82.8m (up 47% from 1Q 2024). Net income: kr10.4m (up 53% from 1Q 2024). Profit margin: 13% (in line with 1Q 2024). Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany.
New Risk • Aug 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (45% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (6.7% average weekly change).
お知らせ • Jul 17EQL Pharma AB (publ), Annual General Meeting, Aug 19, 2024EQL Pharma AB (publ), Annual General Meeting, Aug 19, 2024, at 16:00 W. Europe Standard Time. Location: at the companys premises at stortorget 1, lund Sweden
お知らせ • Jul 05EQL Pharma AB's Key Product Mellozzan[® ](melatonin) Receives Marketing Approval in SwitzerlandEQL Pharma AB's key product Mellozzan®? has now gained marketing approval by the Health Authorities in Switzerland, where it is to be provided to patients by EQL's license partner Medice Arzneimittel Putter GmbH & Co. KG. Launch of Mellozzan in Switzerland is planned for the financial year 2024/25, subject to reimbursement approvals and manufacturing capabilities. In addition to Switzerland the licensee also has ongoing work for registrations and subsequent launches in Finland and the UK. In 2023, Medice launched Mellozzan®? in Denmark and Norway and this year it was launched in Germany and Austria. Mellozzan®? is the first fast-acting melatonin product registered in Switzerland. Since before, slow-acting melatonin has been available for people over 55 with sleep difficulties, but nothing for Mellozzan's normal patient group - children with ADHD and insomnia where sleep hygiene measures have not been sufficient. In addition to the countries covered by Medice, other partners for Mellozzan®? are in various stages of registration in France, Italy, the Netherlands, Turkey and Kazakhstan. Furthermore, EQL has entered into a global license agreement covering about a hundred countries with Adalvo for Mellozzan.
Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €5.06, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 14x in the Healthcare industry in Germany. Total returns to shareholders of 48% over the past three years.
Valuation Update With 7 Day Price Move • May 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €3.61, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 17x in the Healthcare industry in Germany. Total loss to shareholders of 2.4% over the past three years.
Reported Earnings • May 16Full year 2024 earnings released: EPS: kr0.78 (vs kr1.06 in FY 2023)Full year 2024 results: EPS: kr0.78 (down from kr1.06 in FY 2023). Revenue: kr264.2m (up 1.6% from FY 2023). Net income: kr22.7m (down 27% from FY 2023). Profit margin: 8.6% (down from 12% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • May 16Eql Pharma AB (Publ) Provides Sales Guidance for the Year 2024/25EQL Pharma AB (publ) provided sales guidance for the Year 2024/25. For the full year 2024/25, company project a sales growth of around 40%. Achieving this would align with company's long-term sales objectives as outlined in company's five-year financial plan.
Reported Earnings • Feb 14Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: kr70.2m (down 12% from 3Q 2023). Net income: kr6.51m (down 46% from 3Q 2023). Profit margin: 9.3% (down from 15% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 47% p.a. on average during the next 2 years, while revenues in the Healthcare industry in Germany are expected to remain flat.
Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Per Svangren was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Nov 25Investor sentiment improves as stock rises 31%After last week's 31% share price gain to €3.10, the stock trades at a trailing P/E ratio of 35.3x. Average trailing P/E is 20x in the Healthcare industry in Germany. Total returns to shareholders of 25% over the past year.
Reported Earnings • Nov 19Second quarter 2024 earnings released: EPS: kr0.16 (vs kr0.26 in 2Q 2023)Second quarter 2024 results: EPS: kr0.16 (down from kr0.26 in 2Q 2023). Revenue: kr59.6m (down 19% from 2Q 2023). Net income: kr4.68m (down 37% from 2Q 2023). Profit margin: 7.9% (down from 10% in 2Q 2023). The decrease in margin was driven by lower revenue.
Valuation Update With 7 Day Price Move • Nov 09Investor sentiment improves as stock rises 31%After last week's 31% share price gain to €2.67, the stock trades at a trailing P/E ratio of 26.9x. Average trailing P/E is 21x in the Healthcare industry in Germany. Total returns to shareholders of 12% over the past year.
Valuation Update With 7 Day Price Move • Sep 07Investor sentiment deteriorates as stock falls 28%After last week's 28% share price decline to €2.53, the stock trades at a trailing P/E ratio of 27.3x. Average trailing P/E is 20x in the Healthcare industry in Germany. Total loss to shareholders of 2.3% over the past year.
お知らせ • Aug 26+ 2 more updatesEQL Pharma AB (publ) to Report Fiscal Year 2024 Results on May 14, 2024EQL Pharma AB (publ) announced that they will report fiscal year 2024 results on May 14, 2024
New Risk • Aug 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 32% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (32% accrual ratio). Minor Risk Market cap is less than US$100m (€66.7m market cap, or US$72.5m).
Reported Earnings • Jul 26Full year 2023 earnings released: EPS: kr1.06 (vs kr1.09 in FY 2022)Full year 2023 results: EPS: kr1.06 (down from kr1.09 in FY 2022). Revenue: kr259.9m (down 37% from FY 2022). Net income: kr30.9m (down 2.0% from FY 2022). Profit margin: 12% (up from 7.7% in FY 2022). The increase in margin was driven by lower expenses.
お知らせ • Jul 18EQL Pharma AB (publ) to Report Q1, 2024 Results on Aug 16, 2023EQL Pharma AB (publ) announced that they will report Q1, 2024 results on Aug 16, 2023
お知らせ • Jul 07EQL Pharma AB (publ), Annual General Meeting, Aug 17, 2023EQL Pharma AB (publ), Annual General Meeting, Aug 17, 2023, at 16:00 Central European Standard Time. Location: Stortorget 1 Lund Sweden Agenda: To consider the adoption of the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet; the allocation of the company's result in accordance with the adopted balance sheet; to consider resolution on instruction and charter for the Nomination Committee; and to consider other matters.
Reported Earnings • May 14Full year 2023 earnings released: EPS: kr1.06 (vs kr1.09 in FY 2022)Full year 2023 results: EPS: kr1.06 (down from kr1.09 in FY 2022). Revenue: kr259.9m (down 37% from FY 2022). Net income: kr30.9m (down 2.0% from FY 2022). Profit margin: 12% (up from 7.7% in FY 2022). The increase in margin was driven by lower expenses.
Recent Insider Transactions • Mar 29Founder & Chairman recently sold €1.0m worth of stockOn the 24th of March, Christer Fahraeus sold around 300k shares on-market at roughly €3.34 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Christer's only on-market trade for the last 12 months.
Reported Earnings • Nov 13Second quarter 2023 earnings released: EPS: kr0.26 (vs kr0.18 in 2Q 2022)Second quarter 2023 results: EPS: kr0.26 (up from kr0.18 in 2Q 2022). Revenue: kr73.3m (up 40% from 2Q 2022). Net income: kr7.46m (up 39% from 2Q 2022). Profit margin: 10% (in line with 2Q 2022).
お知らせ • Oct 25EQL Pharma AB (publ) Launches One-Step "Lollipop" Antigen Self-Test for Covid-19 in the Nordics - All in One - One Device, One StepEQL Pharma has started to sell the brand new Alltest Covid-19 antigen self-test of the one-step "Lollipop" model, i.e. a test that, like a lollipop, is held in the mouth for two minutes. The test reads oral saliva for Covid-19 and provides an answer within 15 minutes with 99% sensitivity. This is one of the most sensitive self-tests yet for Covid-19, even more sensitive than most of the commonly used nasal swab tests. The test's simplicity and high sensitivity make it suitable for anyone who wishes to test themselves for Covid-19 infection, especially for children and others who feel discomfort from sampling in the nasal cavity. The test is CE marked and sensitive to all known variants of the Covid-19 virus, including Omicron BA.5 which is now the most common variant in Europe. The launch of the lollipop test is seen as a generation shift in EQL Pharma self-diagnostics product line and EQL is the exclusive supplier of the Alltest device in Sweden, Denmark, Finland, Norway, Germany and Ireland. The test is available in leading pharmacies.
Reported Earnings • Aug 18First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr46.1m (up 24% from 1Q 2022). Net income: kr7.39m (up 196% from 1Q 2022). Profit margin: 16% (up from 6.7% in 1Q 2022). The increase in margin was driven by higher revenue.
お知らせ • Aug 18+ 2 more updatesEQL Pharma AB (publ) Announces Executive ChangesEQL Pharma AB (publ) announced Christer Fåhraeus, Founder & CEO, notified the board in the autumn of 2021 that he intends to transition into a board position after the Annual General Meeting (AGM) in August 2022. At that time, the board appointed Axel Schörling, Deputy CEO, as new CEO after Fåhraeus' resignation following the AGM in August 2022. After AGM, Schörling has assumed the position as new CEO in EQL. In connection with this, Martin Kristofferson, previously Director Strategic Sourcing, has been appointed new COO.
お知らせ • Jul 06+ 3 more updatesEQL Pharma AB (publ) to Report Q3, 2023 Results on Feb 14, 2023EQL Pharma AB (publ) announced that they will report Q3, 2023 results on Feb 14, 2023
Reported Earnings • May 15Full year 2022 earnings released: EPS: kr1.09 (vs kr0.36 in FY 2021)Full year 2022 results: EPS: kr1.09 (up from kr0.36 in FY 2021). Revenue: kr409.8m (up 128% from FY 2021). Net income: kr31.5m (up 204% from FY 2021). Profit margin: 7.7% (up from 5.8% in FY 2021). The increase in margin was driven by higher revenue.
お知らせ • May 08EQL Pharma Receives Approval of Glycopyrronium EQL Pharma Solution for Injection 0.2Mg/Ml from Danish Medicines AgencyEQL Pharma announced that it has received the approval of Glycopyrronium EQL Pharma solution for injection 0.2mg/ml from the Danish Medicines Agency and approvals in Sweden, Norway and Finland are expected shortly. Glycopyrronium EQL Pharma contains glycopyrronium bromide and is a so-called anticholinergic which is used in hospital care, among other things, to counteract salivary secretion during operations in the mouth, throat or trachea. Glycopyrronium EQL Pharma will be EQL's third approved inpatient care product and will be sold through public tenderering in all four Nordic countries. The launch is dependent on the result of tenders for procurements but can take place at the earliest in the fourth quarter (January-March) of EQL's financial year.
お知らせ • Apr 26EQL Pharma AB (publ) to Report Fiscal Year 2022 Results on May 13, 2022EQL Pharma AB (publ) announced that they will report fiscal year 2022 results on May 13, 2022
Valuation Update With 7 Day Price Move • Mar 28Investor sentiment improved over the past weekAfter last week's 15% share price gain to €3.20, the stock trades at a trailing P/E ratio of 52.8x. Average trailing P/E is 18x in the Healthcare industry in Germany.
Valuation Update With 7 Day Price Move • Feb 23Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €2.87, the stock trades at a trailing P/E ratio of 48.5x. Average trailing P/E is 19x in the Healthcare industry in Germany.
Reported Earnings • Feb 19Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: kr0.59 (up from kr0.07 in 3Q 2021). Revenue: kr117.6m (up 297% from 3Q 2021). Net income: kr17.2m (up kr15.0m from 3Q 2021). Profit margin: 15% (up from 7.3% in 3Q 2021). Revenue was in line with analyst estimates.
Reported Earnings • Nov 12Second quarter 2022 earnings releasedThe company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2022 results: Revenue: kr52.5m (up 117% from 2Q 2021). Net income: kr5.35m (up 65% from 2Q 2021). Profit margin: 10% (down from 13% in 2Q 2021).
Reported Earnings • Jul 21Full year 2021 earnings released: EPS kr0.36 (vs kr0.09 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: kr179.8m (up 150% from FY 2020). Net income: kr10.4m (up 284% from FY 2020). Profit margin: 5.8% (up from 3.8% in FY 2020).
